Clinical Trial Update: A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a biosimilar CT-P47 to RoActemra (tocilizumab) in rheumatoid arthritis; results from the completed study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CT-P47 (tocilizumab biosimilar)
• RoActemra (tocilizumab)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-08